# Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

> **NCT04845035** · PHASE2 · WITHDRAWN · sponsor: **University of Michigan Rogel Cancer Center**

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Ponatinib
- **DRUG:** Berlin-Frankfurt-Münster Chemotherapy
- **DRUG:** Methotrexate and Cytarabine

## Key facts

- **NCT ID:** NCT04845035
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01
- **Primary completion:** 2026-01
- **Final completion:** 2029-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The PI plans to revise the study design in a new protocol
- **Last updated:** 2024-02-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04845035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04845035, "Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04845035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*